Bedel Financial Consulting’s United Therapeutics UTHR Stock Holding History

Bedel Financial Consulting’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-150	Closed	-$27K	–	869
2022 Q1	$27K	Hold	150	–	–	0.01%	504
2021 Q4	$32K	Hold	150	–	–	0.01%	479
2021 Q3	$28K	Hold	150	–	–	0.01%	492
2021 Q2	$27K	Hold	150	–	–	0.01%	500
2021 Q1	$25K	Hold	150	–	–	0.01%	477
2020 Q4	$23K	Hold	150	–	–	0.01%	436
2020 Q3	$15K	Hold	150	–	–	0.01%	463
2020 Q2	$18K	Hold	150	–	–	0.01%	418
2020 Q1	$14K	Hold	150	–	–	0.01%	433
2019 Q4	$13K	Hold	150	–	–	0.01%	461
2019 Q3	$12K	Hold	150	–	–	0.01%	456
2019 Q2	$12K	Hold	150	–	–	0.01%	471
2019 Q1	$18K	Hold	150	–	–	0.01%	405
2018 Q4	$16K	Hold	150	–	–	0.01%	394
2018 Q3	$19K	Hold	150	–	–	0.01%	388
2018 Q2	$17K	Buy	+150	New	+$16.5K	0.01%	404

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bedel Financial Consulting's UTHR Position: Q2 2022 in Review

Bedel Financial Consulting sold out of United Therapeutics (UTHR) in Q2 2022, closing a stake of 150 shares — an estimated $27K sold.

Bedel Financial Consulting first reported a position in UTHR in Q2 2018 and held it in 16 quarters. The position peaked at $32K in Q4 2021. 472 funds tracked by Wall St. Rank hold UTHR as of Q2 2022.

Bedel Financial Consulting reported no remaining United Therapeutics position as of Q2 2022 after selling out during the quarter.
Bedel Financial Consulting sold 150 United Therapeutics shares in Q2 2022, an estimated $27K.
Bedel Financial Consulting first reported a position in United Therapeutics in Q2 2018 and held it in 16 quarters.
Bedel Financial Consulting's United Therapeutics position peaked at $32K in Q4 2021.
472 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.